奥赛康：子公司与阿诺医药达成AN9025项目许可引进协议

Core Viewpoint - Aosaikang (002755) has entered into a licensing agreement with Hangzhou Anuo Biopharmaceutical Technology Co., Ltd. for the exclusive rights to develop, produce, and commercialize the innovative drug AN9025 within the licensed area [1] Group 1: Agreement Details - Aosaikang's subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., will pay a non-refundable upfront fee of 35 million yuan to Anuo Biopharmaceutical within 10 working days after the agreement takes effect [1] - The total milestone payments related to product development, registration, and market launch will not exceed 470 million yuan [1] - Additional payments related to achieving certain sales milestones will not exceed 1.128 billion yuan [1]